Please login to the form below
A Pharma Marketer's Guide to the Mobile Web
Despite an acknowledgement of the importance of mobile by the pharma sector, there has been little evidence to show that businesses are harnessing the mobile web effectively, instead opting for mobile app development. This guide sheds some light on mobile web opportunities for Pharma.
Find out what you could be doing to
develop your mobile presence effectively, by downloading A
Pharma Marketer's Guide to the Mobile Web, which was first published in November 2012.
High-level findings include:
- Patients’ needs for content are poorly served: only two European sites (both
concerned with contraception, from HRA and MSD UK) seem to recognise and
address patient audiences, though they serve these needs to widely differing
standards.
- Responsive design techniques for developing cross-device content are
under-represented: Astellas stands out strongly for its European corporate level
sites.
- Users with feature-phones are largely ignored: only Shire.com (providing
investor information) offers a mobile resource fully accessible and usable through
these devices.
- Mobile is (too often) an island: typically, mobile optimisation is reserved for a
single site in a company’s brand portfolio (the global, corporate.com) and when a
browsing journey leads to other properties (e.g. careers, investor or product – let
alone patient – info) the user is passed to a desktop site. It’s also an island where
the natives only speak English.
- Attention to detail is low across all sites: while homepages tend to look
attractive, our review highlights examples both of failure to implement W3C mobile
best practices (such as making all numbers click to call and providing links back
to a full site) and of flawed user acceptance testing which hasn’t detected broken
or missing links.
High-level findings include:
- Patients’ needs for content are poorly served: only two European sites (both
concerned with contraception, from HRA and MSD UK) seem to recognise and
address patient audiences, though they serve these needs to widely differing
standards.
- Responsive design techniques for developing cross-device content are
under-represented: Astellas stands out strongly for its European corporate level
sites.
- Users with feature-phones are largely ignored: only Shire.com (providing
investor information) offers a mobile resource fully accessible and usable through
these devices.
- Mobile is (too often) an island: typically, mobile optimisation is reserved for a
single site in a company’s brand portfolio (the global, corporate.com) and when a
browsing journey leads to other properties (e.g. careers, investor or product – let
alone patient – info) the user is passed to a desktop site. It’s also an island where
the natives only speak English.
- Attention to detail is low across all sites: while homepages tend to look
attractive, our review highlights examples both of failure to implement W3C mobile
best practices (such as making all numbers click to call and providing links back
to a full site) and of flawed user acceptance testing which hasn’t detected broken
or missing links.
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Diagnosing the lag in neuropsychiatric treatments
- The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.
Blue Latitude Health
- Precision paediatrics: Treating patients with CAR-T
- Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
Blue Latitude Health
- What does it mean to be an agile organisation
- We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Blue Latitude Health
- Battling breast cancer with precision medicine (Part 2)
- Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.
Blue Latitude Health
- Battling breast cancer with precision medicine (Part 1)
- Laura Holmes Haddad is a breast cancer survivor. She made the incredibly brave decision to participate in a PARP inhibitor precision medicine trial. Here, the author and precision medicine advocate tells her story and explains what industry needs to remember when treating cancer patients with precision medicine.
Blue Latitude Health
- The role of brain health in treating MS
- Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health, the importance of a holistic approach to MS and why digital technology is the future of effective MS care.
Blue Latitude Health
